Ignite Creation Date:
2025-12-25 @ 5:00 AM
Ignite Modification Date:
2025-12-26 @ 4:00 AM
Study NCT ID:
NCT04441918
Status:
UNKNOWN
Last Update Posted:
2020-06-22
First Post:
2020-06-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
Sponsor:
Shanghai Junshi Bioscience Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-06-05
Start Date Type:
ACTUAL
Primary Completion Date:
2020-12-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2020-12-11
Completion Date Type:
ESTIMATED
First Submit Date:
2020-06-06
First Submit QC Date:
None
Study First Post Date:
2020-06-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-06-18
Last Update Post Date:
2020-06-22
Last Update Post Date Type:
ACTUAL